PBR - Clinical Trials News
Sperogenix Therapeutics, the company’s rare disease partner in China, filed the application with the NMPA. The Center for Drug Evaluation (CDE) of the NMPA accepted the filing after The post Santhera’s vamorolone NDA receives priority review in China appeared first on Pharmaceutical Business review.
This collaboration is expected to leverage Cipla’s extensive distribution network to enhance the reach of Sanofi India’s CNS products. Under the agreement, Cipla will handle the distribution and The post Cipla enters deal to distribute Sanofi’s CNS products in India appeared first on Pharmaceutical Business review.
With the deal closing, the merged business will now function under the name Q32 Bio. Concurrent with the merger’s closure, Q32 Bio also finalised a $42m private placement. The post Q32 Bio concludes merger deal with Homology Medicines appeared first on Pharmaceutical Business review.
This endorsement is a significant step towards the availability of Fabhalta for PNH patients in Europe. The positive opinion is based on data from two Phase III clinical The post EMA CHMP recommends marketing authorisation for Novartis’ PNH treatment appeared first on Pharmaceutical Business review.
This development marks the first nonsteroidal medication authorised to treat DMD patients with all genetic variants of a rare neurological disorder. A histone deacetylase (HDAC) inhibitor, Duvyzat can The post FDA approves Italfarmaco’s Duvyzat for DMD treatment appeared first on Pharmaceutical Business review.
EVO756 is a highly selective small molecule antagonist targeting mas-related G-protein coupled receptor X2 (MRGPRX2), a receptor implicated in various inflammatory conditions. This partnership builds on a previous The post Evommune expands EVO756 collaboration with Maruho in Asia appeared first on Pharmaceutical Business review.
Build your own newsfeed
Ready to give it a go?
Start a 14-day trial, no credit card required.